|Daily Range||$35.67 - $35.95|
|52-Week Range||$32.08 - $38.15|
|Dividend (Yield)||$0.00 (2.3%)|
|Average Daily Volume||833,700|
|Current FY EPS||$1.88|
News & Commentary
Global cancer drug sales could soon soar past $100 billion, making this pure play in cancer drugs a stock you should seriously consider owning.
Healthcare stocks with plenty of potential -- and low share prices
Making money helping people shed the pounds.
Chemotherapy is a cancer treatment staple, but a recently published study suggests a combination of two treatments could provide the same benefit as chemotherapy with possibly far fewer side effects.
Small cap biotech stocks have a lot of inherent risk, but if you can snag a winner your returns could double many times over. Here's one small-cap biotech stock you can consider buying and holding for the next 10 years.
These three biotechs have promising drugs in their pipelines that address billion dollar drug markets.
Phase 1 trial results for Prothena Corporation's PRX-002 could indicate that this drug may help treat Parkinson's disease someday.
Takeda Pharmaceutical has licensed ImmunoGen's antibody-drug conjugate technology.
With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.
Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.